Compare Nokia Corp (NOK) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Repligen Corporation Common Stock — how do they compare? Nokia Corp trades at $9.31 (market cap $54.48B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Nokia Corp is far larger — about 4.8× Repligen Corporation Common Stock's market cap, and Nokia Corp pays a 1.74% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 65 Days and Repligen Corporation Common Stock for 0 Days on average.
| NOK | RGEN | |
|---|---|---|
Market Cap | $54.48B | $11.31B |
Volume | 85,996,980 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $16.83 | $194.57 |
52-Week Low | $5.55 | $102.87 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $52.50B | $11.20B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $9.86, down 0.4% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights partnerships in AI and satellite communications, including expanded collaboration with Microsoft and a defense-focused satellite venture with ICEYE.
The stock presents a valuation gap with a high P/E of 70.19 but strong analyst support, with a consensus price target of $17.50 implying significant upside. Key risks include competitive pressures in telecom equipment and fluctuating cash flows, while catalysts include AI infrastructure demand and strategic partnerships driving future growth.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
